Diffusivity in multiple sclerosis lesions: At the cutting edge?

Alexander Klistorner1, Chenyu Wang2, Vera Fofanova3

  • 1Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, Australia; Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

Neuroimage. Clinical
|August 5, 2016
PubMed
Abstract

Insights

Radial diffusivity (RD) in MS lesions is affected by tissue destruction, masking remyelination. The T2 lesion edge, less affected by tissue loss, is a better target for imaging biomarkers of de- and remyelination.

Area of Science:

  • Neuroimaging
  • Biomarker Development
  • Multiple Sclerosis Research

Background:

  • Radial diffusivity (RD) is a potential biomarker for myelination in MS lesions.
  • However, RD is influenced by both myelin loss and tissue destruction, potentially obscuring remyelination effects.

Purpose of the Study:

  • To investigate if the T2 lesion edge (T1-isointense rim) is a more suitable region than the T1-hypointense core for imaging biomarkers of de- and remyelination.
  • Hypothesizing that the T2 lesion edge is less affected by tissue loss.

Main Methods:

  • Diffusion tensor imaging (DTI) and contrast-enhanced T1/T2 MRI were acquired from 75 RRMS patients.
  • T2 lesions were segmented into T1-hypointense (core) and T1-isointense (rim) areas.
  • Diffusivity metrics (RD, AD, MD) and FA were calculated for lesion components, excluding enhancing lesions.

Main Results:

  • Chronic T2 lesions predominantly featured a T1-hypointense core (approx. 40% volume) and a peripheral T1-isointense "T2-rim".
  • The "T2-rim" showed a disproportionately higher increase in RD compared to AD relative to normal white matter.
  • Diffusivity increases were similar between the "T2-rim" and the T1-hypointense core.

Conclusions:

  • Distinct diffusivity patterns suggest axonal loss dominates the T1-hypointense lesion core.
  • The "T2-rim" may better reflect de/remyelination due to preserved structural integrity.
  • Separating these lesion components is crucial for evaluating neuroprotective and remyelinating therapies in MS clinical trials.

Related Concept Videos